Bioidentical Does Not Always Mean Compounded: How to Compare Menopause Hormone Options

You may hear natural, bioidentical, compounded, and customized used almost interchangeably when looking into menopause treatment. They do not mean the same thing. The most useful distinction is that bioidentical describes a hormone’s chemical structure, while compounded describes a method of preparing a medication. Some FDA-approved hormone medicines are bioidentical. A compounded preparation is not FDA-approved simply because its ingredients resemble hormones your body produces.

That distinction matters more than which phrase sounds reassuring. Before agreeing to treatment, you should know the exact drug, why it was selected, what evidence applies to it, and how its benefits and risks will be reviewed. This guide focuses on menopausal hormone therapy; testosterone treatment for men involves a separate evaluation and should not be folded into the same discussion.

Ask what is being prescribed, in plain language

Request the generic hormone name, brand if applicable, delivery form, and whether the finished medication is FDA-approved or compounded. Estradiol and progesterone are examples of hormones available in FDA-approved formulations, but that does not mean every preparation containing those names is an approved product. A label or written prescription is more informative than the umbrella term BHRT.

Make a short comparison sheet. In one column, write the product being recommended. In another, write the symptom it is intended to address. Add the proposed follow-up, estimated total cost, and alternatives. If any of those boxes remain unclear, ask for an explanation before deciding. You do not need to memorize pharmacology to ask for a transparent treatment plan.

Compounding is a separate regulatory question

ACOG advises against routinely using compounded bioidentical menopausal hormone therapy when FDA-approved formulations are available. Compounded drugs do not undergo the same FDA premarket review for safety, effectiveness, and quality as approved products. A clinician may identify a specific need that an available approved product does not meet, but customization alone is not evidence of superiority.

Ask: what patient-specific problem would compounding solve in my case, and why would an approved alternative not meet that need? Also ask who prepares the medication and how concerns about supply, consistency, or side effects are handled. A thoughtful answer should address your situation rather than suggesting all compounded medicines are better or all conventional medicines are unsuitable.

The route matters as well as the ingredient

Tablets, skin patches, gels, vaginal products, and implanted preparations are not interchangeable merely because they are described as hormones. Ask where the medication acts, how it is absorbed, how it can be adjusted, and what happens if you want to stop. A treatment that is difficult to change quickly deserves a particularly clear discussion before use.

The FDA distinguishes systemic treatment, which reaches the body more broadly, from local vaginal options used for certain genitourinary symptoms. For someone with a uterus, systemic estrogen usually requires appropriate protection of the uterine lining with a progestogen. These are clinical decisions, not product preferences to settle through an online quiz. Bring your surgical history and the names of any current hormone medications.

Natural is not a safety guarantee

No reassuring adjective removes the need to review medical history. Discuss unexplained bleeding, prior blood clots or stroke, liver disease, hormone-sensitive cancer history, and current medications. Treatment risks depend on the person and the specific regimen. An educational blog cannot decide candidacy from age or symptoms alone.

FDA communications and product labeling can change. Rather than relying on an old screenshot of a warning or an advertisement saying warnings have disappeared, ask the prescriber to explain the current label for the actual medication. The practical question is how its benefits and risks apply to you now. Nonhormonal options should also be part of the conversation where appropriate.

Define success before you compare packages

Suppose the main problem is waking repeatedly with night sweats. A useful plan would identify how you will track that symptom and when you will reassess it. A promise to optimize every aspect of energy, appearance, and aging is too vague to evaluate. Choose concrete goals and agree on what would prompt a change of approach.

Ask what expenses are separate: consultation, medication, any procedure, follow-up, and clinically indicated testing. Compare the whole plan rather than a single advertised monthly amount. You should also know whom to contact between visits and how to report a new symptom. Paying for a program does not replace the need for ongoing clinical decisions.

Bring these questions to Harmony

• What exact medication are you recommending, and is the finished product FDA-approved?
• Which symptom is it intended to treat, and what alternatives are reasonable?
• If it is compounded, what specific need makes that appropriate for me?
• How does my history change the risk discussion?
• How can the treatment be adjusted or stopped if necessary?
• What follow-up and costs should I plan for?

Harmony Med Spa offers hormone consultations in Sarasota. Use the visit to understand your options, not to arrive committed to a particular formulation. This is educational material for discussion with a qualified prescriber, not a recommendation to start, stop, or change medication.

Sources and further reading

ACOG: compounded bioidentical menopausal hormone therapy: https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy

FDA: menopausal hormone treatment options: https://www.fda.gov/consumers/consumer-updates/hormone-replacement-therapies-can-help-women-bothersome-menopausal-symptoms

FDA: evaluation of compounded bioidentical hormone evidence: https://www.fda.gov/drugs/human-drug-compounding/national-academies-science-engineering-and-medicine-nasem-study-clinical-utility-treating-patients